A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C

Yi-Ming Chen; Hsin-Hua Chen; Yi-Hsing Chen; Tsu-Yi Hsieh; Chia-Wei Hsieh; Wei-Ting Hung; Joung-Liang Lan; Der-Yuan Chen

doi:10.1136/annrheumdis-2014-206711

A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C

Ann Rheum Dis. 2015 Mar;74(3):626-7. doi: 10.1136/annrheumdis-2014-206711. Epub 2014 Dec 1.

Authors

Yi-Ming Chen¹, Hsin-Hua Chen², Yi-Hsing Chen², Tsu-Yi Hsieh³, Chia-Wei Hsieh⁴, Wei-Ting Hung³, Joung-Liang Lan⁵, Der-Yuan Chen⁶

Affiliations

¹ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine, National Yang Ming University, Taipei, Taiwan Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
² Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine, National Yang Ming University, Taipei, Taiwan.
³ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.
⁴ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
⁵ Division of Immunology and Rheumatology, China Medical University Hospital, Taichung, Taiwan College of Medicine, China Medical University, Taichung, Taiwan.
⁶ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine, National Yang Ming University, Taipei, Taiwan Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan Institute of Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan.

PMID: 25452310
DOI: 10.1136/annrheumdis-2014-206711

No abstract available

Keywords: Anti-TNF; DMARDs (biologic); Rheumatoid Arthritis.

Publication types

Comparative Study
Letter

MeSH terms

Adalimumab
Aged
Aged, 80 and over
Alanine Transaminase / blood
Alanine Transaminase / drug effects
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Murine-Derived / adverse effects*
Antibodies, Monoclonal, Murine-Derived / pharmacology
Antirheumatic Agents / adverse effects*
Antirheumatic Agents / pharmacology
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy*
Etanercept
Female
Hepatitis C, Chronic / blood
Hepatitis C, Chronic / complications*
Humans
Immunoglobulin G / adverse effects*
Immunoglobulin G / pharmacology
Male
Middle Aged
Receptors, Tumor Necrosis Factor
Rituximab
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Viral Load / drug effects

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Rituximab
golimumab
Alanine Transaminase
Adalimumab
Etanercept